Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 11Prostatic Neoplasms 7Fallopian Tube Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Carcinoma, Ovarian Epithelial 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1SCLC,Extensive Stage 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Carcinosarcoma 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Lung Neoplasms 1Laryngeal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Hemangiosarcoma 1Head and Neck Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1

Interventions

darolutamide 2Docetaxel 2Androgen Antagonists 2niraparib 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Hormone-sensitive Prostate Cancer (mHSPC) × niraparib × 90 days × Clear all
NCT06392841 2026-04-08

HARMONY

Hoosier Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡